A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
Trial details
- Registry ID
- NCT04374136
- Drugs studied
- Part 1 Blinded - AL001, Part 2 (OLE Treatment) - AL001
TrialRedline tracks 6 clinical trials sponsored by Alector Inc.: 2 Phase 3, 4 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)NCT04374136 | Part 1 Blinded - AL001, Part 2 (OLE Treatment) - AL001 | Terminated | 2025-09-01Actual |
| Continuation Study for LatozinemabNCT06111014 | Latozinemab | Terminated | 2025-09-01Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's DiseaseNCT04592874 | AL002 | Completed | 2024-08-19Actual |
| A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)NCT03987295 | AL001 | Completed | 2024-06-05Actual |
| A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's DiseaseNCT05744401 | AL002 | Terminated | 2025-01-31Actual |
| A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALSNCT05053035 | AL001 | Terminated | 2022-10-28Actual |
Names as written in the registry records.
NCT04374136 · Alector Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Evaluation of efficacy of AL001 as measured by the CDR® plus NACC FTLD-SB. After: Measure: Part 1 Double Blind - Evaluation of Efficacy of AL001 Compared With Placebo as Measured by the CDR® Plus NACC FTLD-SB in Symptomatic Patients Measure: Part 1 Double Blind (Co-Primary US Endpoint) - Evaluation of the Treatment Effect of AL001 Compared With Placebo as Measured by Pharmacodynamic and Disease Pathology Biomarkers in Symptomatic Patients Measure: Part 2 OLE - To Assess the Long-term Safety and Tolerability of AL001 in Participants Who Have Completed Part 1 of the Study.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Safety and Tolerability as Measured by Number of Treatment-expected Adverse Events (TEAE) and Treatment-related Adverse Events (AEs). Measure: Safety and Tolerability as Measured by Number of Adverse Events of Special Interest and Serious Adverse Events Measure: Safety and Tolerability as Measured by the Number of Cases of Abnormal Vital Signs, Clinical Laboratory Results and Findings From Physical, Neurological, Ophthalmological Examinations and Electrocardiograms. Measure: To Evaluate the Long-term Safety and Tolerability of AL002 by Assessing Suicidality Using the Columbia-Suicide Severity Rating Scale (C-SSRS) Measure: To Evaluate the Effect of Dose Titration on the Occurrence of ARIA-E Measure: To Evaluate the Effect of Dose Titration on the Occurrence of ARIA-H. After: Measure: Safety and Tolerability as Measured by Number of Treatment-expected Adverse Events (TEAE) and Treatment-related Adverse Events (AEs). Measure: Safety and Tolerability as Measured by Number of Adverse Events of Special Interest and Serious Adverse Events Measure: Safety and Tolerability as Measured by the Number of Cases of Abnormal Vital Signs, Clinical Laboratory Results and Findings From Physical, Neurological, Ophthalmological Examinations and Electrocardiograms. Measure: To Evaluate the Long-term Safety and Tolerability of AL002, by Assessing the Number of Suicidal Risk Events Using the Columbia-Suicide Severity Rating Scale (C-SSRS) Measure: To Evaluate the Effect of Dose Titration on the Occurrence of ARIA-E by Assessing the Number of Participants With ARIA-E Events Measure: To Evaluate the Effect of Dose Titration on the Occurrence of ARIA-H by Assessing the Number of Participants With ARIA-H Events.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Safety and Tolerability as Measured by Number of/Incidence of Treatment-expected Adverse Events (TEAE) and Treatment-related Adverse Events (AEs). Measure: Safety and Tolerability as Measured by Number of/Incidence of Adverse Events of Special Interest and Serious Adverse Events Measure: Safety and Tolerability as Measured in Evaluation of Vital Signs, Clinical Laboratory Results and Findings From Physical, Neurological, Ophthalmological Examinations and Electrocardiograms. Measure: To Evaluate the Long-term Safety and Tolerability of AL002 Utilizing the Columbia-Suicide Severity Rating Scale (C-SSRS) Measure: To Evaluate the Effect of Dose Titration on ARIA-E Measure: To Evaluate the Effect of Dose Titration on ARIA-H. After: Measure: Safety and Tolerability as Measured by Number of Treatment-expected Adverse Events (TEAE) and Treatment-related Adverse Events (AEs). Measure: Safety and Tolerability as Measured by Number of Adverse Events of Special Interest and Serious Adverse Events Measure: Safety and Tolerability as Measured by the Number of Cases of Abnormal Vital Signs, Clinical Laboratory Results and Findings From Physical, Neurological, Ophthalmological Examinations and Electrocardiograms. Measure: To Evaluate the Long-term Safety and Tolerability of AL002 by Assessing Suicidality Using the Columbia-Suicide Severity Rating Scale (C-SSRS) Measure: To Evaluate the Effect of Dose Titration on the Occurrence of ARIA-E Measure: To Evaluate the Effect of Dose Titration on the Occurrence of ARIA-H.
NCT04374136 · Alector Inc.
Before: Estimated. After: Actual.
Before: 110 participants (planned). After: 119 participants (actual).
Before: Estimated. After: Actual.
Before: Active not recruiting. After: Terminated.
NCT06111014 · Alector Inc.
Before: Estimated. After: Actual.
Before: 35 participants (planned). After: 17 participants (actual).
Before: Estimated. After: Actual.
Before: 30 Jul 2027. After: 1 Sep 2025.
Before: Enrolling by invitation. After: Terminated.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Safety and tolerability as measured by number of/incidence of Adverse Events (AEs), including AESI and SAEs. Measure: Safety and tolerability as measured by the number of incidence/MRI abnormalities.. After: Measure: Safety and Tolerability as Measured by Number of/Incidence of Treatment-expected Adverse Events (TEAE) and Treatment-related Adverse Events (AEs). Measure: Safety and Tolerability as Measured by Number of/Incidence of Adverse Events of Special Interest and Serious Adverse Events Measure: Safety and Tolerability as Measured in Evaluation of Vital Signs, Clinical Laboratory Results and Findings From Physical, Neurological, Ophthalmological Examinations and Electrocardiograms. Measure: To Evaluate the Long-term Safety and Tolerability of AL002 Utilizing the Columbia-Suicide Severity Rating Scale (C-SSRS) Measure: To Evaluate the Effect of Dose Titration on ARIA-E Measure: To Evaluate the Effect of Dose Titration on ARIA-H.
Before: 198 participants (actual). After: 197 participants (actual).